lLke I posted ,Biotech in $2's for 2 Year Survival Rate VERY undervalued by Wall Street.
Bloomberg Tweet / SRPT Has Delivered to FDA Exactly What They Asked For / POST
Caroline ChenVerified account
@CarolineYLChen BloombergCEO told me yesterday his focus: "we made sure we gave [FDA] exactlywhat they asked for."
Achillion Enters Into Worldwide Collaboration for Hepatitis C With J & J
Achillion Pharmaceuticals, Inc.
1 hour agoGlobeNewswire
J&J buys into Achillion's hep C pipeline for up to $1.1B
May 19, 2015 | By Damian Garde
Johnson & Johnson ($JNJ), fighting to keep up with the blockbuster race to launch quick cures for hepatitis C, has agreed to pay as much as $1.1 billion for the rights to Achillion Pharmaceuticals' ($ACHN) pipeline of antiviral treatments.
Under the deal, J&J is making a $225 million investment in its partner and promising up to $905 million in milestone payments in order to get its hands on a group of in-development hep C treatments. The plan is to develop Achillion's drugs in combination with one another and, ideally, come up with a regimen thatcan cure the infection in as few as four weeks. Leading the pipeline is ACH-3102, Achillion's Phase II NS5A inhibitor, followed by the complementary ACH-3422 and sovaprevir.
This Is the Big Gun Folks, the list goes on and on
Investor Business Daily
CyberArk serves some 1,800 customers, including 40 of the Fortune 100 companies and 17 of the top 20 global banks.